BCR and B-cell chronic lymphocytic leukemia: Fostamatinib reduces the phosphorylation of the proximal BCR signaling regulators SLP65 and PLCγ2, in addition to ERK, AKT, and NF-κB downstream pathways, eventually, decreases proliferation and survival of CLL cells [32].